In fiscal 2026, which ended May 31, 2026, Tilray Brands, Inc. reported revenue of $915.5 million, up 11.5% from the year before. It recorded a net loss of $121.4 million. The operating loss came to $63.0 million, an operating margin of -6.9%. Diluted earnings per share were -$1.09. Over the twelve months ended Aug 31, 2026, revenue was $963.1 million and the net loss was $164.2 million. Across the 9 fiscal years shown, revenue grew from $43.1 million in fiscal 2018 to $915.5 million in fiscal 2026, about 46.5% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2027
Aug 31, 2026
|
FY 2026
May 31, 2026
|
FY 2025
May 31, 2025
|
FY 2024
May 31, 2024
|
FY 2023
May 31, 2023
|
FY 2022
May 31, 2022
|
FY 2021
May 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
963
+15.9%
|
915
+11.5%
|
821
+4.1%
|
789
+25.8%
|
627
-0.2%
|
628
+22.5%
|
513
+143.8%
|
210
+26.1%
|
167
+287.2%
|
43
|
| Cost of revenue |
683
+15.2%
|
655
+12.8%
|
581
+2.7%
|
566
+17.8%
|
480
-6.1%
|
512
+31.2%
|
390
+109.8%
|
186
|
—
|
29
|
| Gross profit |
280
+17.7%
|
260
+8.3%
|
241
+7.7%
|
223
+52.0%
|
147
+25.8%
|
117
-5.2%
|
123
+399.6%
|
25
+204.9%
|
-23
-264.6%
|
14
|
| Research and development |
0
+85.9%
|
0
+27.1%
|
0
-55.3%
|
1
-6.9%
|
1
-55.1%
|
2
+82.9%
|
1
-81.2%
|
4
-51.9%
|
9
+56.4%
|
6
|
| Selling, general and administrative |
270
+22.0%
|
253
+13.2%
|
223
+9.2%
|
205
+2.3%
|
200
+1.1%
|
198
+43.1%
|
138
-1.7%
|
141
-19.6%
|
175
+171.3%
|
64
|
| Restructuring and impairment |
15
-52.5%
|
13
-61.8%
|
34
+120.0%
|
16
+68.5%
|
9
|
—
|
—
|
—
|
—
|
—
|
| Operating income |
-89
+96.0%
|
-63
+97.2%
|
-2,283
-1206.3%
|
-175
+87.2%
|
-1,370
-124.4%
|
-610
-361.8%
|
-132
+34.3%
|
-201
+33.9%
|
-304
-425.8%
|
-58
|
| Interest income |
—
|
6
-45.1%
|
11
-11.3%
|
13
-61.1%
|
33
+181.4%
|
12
|
—
|
1
+435.6%
|
0
|
—
|
| Interest expense |
—
|
30
-27.6%
|
41
-16.1%
|
49
+5.7%
|
47
+17.5%
|
40
|
—
|
—
|
—
|
—
|
| Other non-operating income (expense) |
—
|
-1
-113.3%
|
10
+127.2%
|
-38
+43.4%
|
-67
-133.8%
|
198
+206.9%
|
-185
-1688.8%
|
-10
-513.2%
|
3
+24.4%
|
2
|
| Pretax income |
-126
+94.5%
|
-88
+96.2%
|
-2,302
-824.6%
|
-249
+82.8%
|
-1,450
-229.1%
|
-441
-27.7%
|
-345
-24.7%
|
-277
+16.1%
|
-330
-356.7%
|
-72
|
| Income tax |
21
+117.0%
|
17
+114.1%
|
-121
-354.7%
|
-27
-270.6%
|
-7
-9.8%
|
-7
+27.1%
|
-9
-60.2%
|
-6
+33.7%
|
-8
-89.8%
|
-4
|
| Net income |
-164
+92.4%
|
-121
+94.4%
|
-2,187
-792.6%
|
-245
+83.1%
|
-1,453
-204.7%
|
-477
-29.8%
|
-367
-35.5%
|
-271
+15.6%
|
-321
-374.2%
|
-68
|
| Basic EPS |
-1.38
-106.7%
|
-1.09
+95.6%
|
-24.56
-644.2%
|
-3.30
-40.4%
|
-2.35
-137.4%
|
-0.99
+27.2%
|
-1.36
|
—
|
—
|
—
|
| Diluted EPS |
-1.38
-106.7%
|
-1.09
+95.6%
|
-24.56
-644.2%
|
-3.30
-40.4%
|
-2.35
-137.4%
|
-0.99
+27.2%
|
-1.36
|
—
|
—
|
—
|
| Weighted average shares, basic |
119
+214.8%
|
112
+25.6%
|
89
+19.9%
|
74
-88.0%
|
618
+28.4%
|
481
+78.5%
|
270
|
—
|
—
|
—
|
| Weighted average shares, diluted |
119
+214.8%
|
112
+25.6%
|
89
+19.9%
|
74
-88.0%
|
618
+28.4%
|
481
+78.5%
|
270
|
—
|
—
|
—
|
| Other measures | ||||||||||
| Depreciation and amortization |
—
|
—
|
—
|
—
|
—
|
155
+127.9%
|
68
+263.6%
|
19
+17.7%
|
16
+344.9%
|
4
|
| EBITDA |
—
|
—
|
—
|
—
|
—
|
-456
-608.4%
|
-64
+64.7%
|
-182
+36.7%
|
-288
-431.1%
|
-54
|
| Interest coverage |
—
|
-2.11x
|
-55.23x
|
-3.55x
|
-29.38x
|
-15.38x
|
—
|
—
|
—
|
—
|
| Margins | ||||||||||
| Gross margin |
29.12%
|
28.45%
|
29.29%
|
28.31%
|
23.43%
|
18.59%
|
24.01%
|
11.71%
|
-14.07%
|
33.10%
|
| Operating margin |
-9.26%
|
-6.88%
|
-277.93%
|
-22.15%
|
-218.41%
|
-97.14%
|
-25.76%
|
-95.55%
|
-182.14%
|
-134.11%
|
| Pretax margin |
-13.04%
|
-9.62%
|
-280.33%
|
-31.56%
|
-231.24%
|
-70.13%
|
-67.24%
|
-131.45%
|
-197.40%
|
-167.34%
|
| Profit margin |
-17.05%
|
-13.26%
|
-266.25%
|
-31.05%
|
-231.64%
|
-75.88%
|
-71.61%
|
-128.79%
|
-192.34%
|
-157.02%
|
| EBITDA margin |
—
|
—
|
—
|
—
|
—
|
-72.54%
|
-12.54%
|
-86.69%
|
-172.65%
|
-125.85%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- TLRY (Nasdaq)
- Fiscal year ends
- May 31
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1731348
- Former names
- Tilray, Inc. (until Jan 10, 2022)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.